M&T Bank
ALXN

M&T Bank’s Alexion Pharmaceuticals ALXN Stock Holding History

M&T Bank’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-5
Closed -$2K – 1707
2017
Q3 		$2K Buy
+5
New +$679 ﹤0.01% 1599

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

M&T Bank's ALXN Position: Q3 2021 in Review

M&T Bank sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 11,415 shares — an estimated $2.1M sold.

M&T Bank first reported a position in ALXN in Q2 2013 and held it in 32 quarters. The position peaked at $6.46M in Q4 2014. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • M&T Bank reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • M&T Bank sold 11,415 Alexion Pharmaceuticals shares in Q3 2021, an estimated $2.1M.
  • M&T Bank first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 32 quarters.
  • M&T Bank's Alexion Pharmaceuticals position peaked at $6.46M in Q4 2014.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on M&T Bank's 13F filing for Q3 2021, filed 28 Oct 2021.